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Introduction
Hepatocellular carcinoma (HCC) is responsible for 
approximately 90% of primary liver cancers and is the 
second most common cause of cancer related deaths, 
worldwide (1). Although it is historically associated 
with viral infections, the incidence of HCC in western 
populations is expected to rise due to the increasing 
prevalence of noncommunicable diseases which are linked 
to this malignancy. Such diseases include obesity, diabetes, 
non-alcoholic fatty and alcoholic liver disease (2).
There have been recent changes to the available 
t r e a t m e n t  o p t i o n s  f o r  H C C  w i t h  c o n c o m i t a n t 
improvements in outcome of patients with early disease. 
However, the overall prognosis of HCC remains generally 
poor, and is correlated with presenting stage. As such, early 
detection of the disease has been shown to be a significant 
clinical challenge. A diagnostic marker which has the 
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capacity to detect early stage cancer is thus likely to alter 
the prognosis of HCC (3,4).
The current method by which HCC is diagnosed is 
primarily based on imaging methods. Whilst useful, they 
have a number of limitations. Ultrasound is operator 
dependent and the sensitivity may be diminished due to 
body habitus. Although CT scan has demonstrated marked 
increase in sensitivity and specificity in comparison to 
US scan, studies have indicated an indirect correlation to 
tumour size which limits its ability in diagnosis of early 
cancers (5). MRI is more sensitive (6), however, these scans 
are expensive, time consuming and are resource constrained.
A number of candidate markers are available which may 
represent breakthroughs in future HCC diagnosis and 
management. Blood borne tumour markers in the form of 
circulating tumour cells (CTCs) (7) and cell free nucleic 
acids (cfDNA) (8) are topics of intense research. Each may 
allow for strategies to detect cancers in early stages, measure 
treatment progress, and offer prognosis post treatment. 
CTCs have been identified as playing a large role in 
metastasis and recurrence via their nature of shedding of the 
primary tumour into blood, lymph and bone marrow which 
allows circulation to other parts of the body (8). However, 
as a tumour marker, detection of CTCs remains limited at 
best due to the lack of volume sensitivity in early stage HC, 
and a wide specific detection range complicated by common 
hepatic diseases associated with HCC (7).
CTCs are suggested to hold exciting potentials and many 
studies have been conducted to discover new possibilities. 
However, the sensitivity and specificity remain unclear. To 
ensure high fidelity in this novel topic, this meta-analysis 
aims to determine the diagnostic accuracy of CTC in the 
diagnosis of HCC.
Methods
This was a meta-analysis carried out according to the 
PRIMA guidelines (9).
Eligibility criteria and outcomes
Studies eligible for the analysis were defined using the 
Population, Intervention, Comparison and Outcome 
strategy (PICO) (10). The study population was adults 
who were diagnosed with HCC via current gold standards 
methods of detection. Type of intervention was the use of 
CTCs in the detection of HCC. Comparator was individual 
CTC performance in the study. The primary outcome was 
the overall sensitivity and specificity of HCC detection 
with tumour specific single gene methylation alteration. 
Secondary outcomes were the comparison using specific 
assay methods, early vs. late HCC stage and specific TNM 
staging and Youden index.
Inclusion criteria
Studies were included if they matched all of the following: 
(I) all patients were diagnosed with HCC; (II) samples 
taken were from peripheral blood; (III) sufficient data was 
available to assess sensitivity and specificity of the CTC or 
data were available to calculate from primary data.
Studies were excluded if insufficient data for describing 
or calculating sensitivity and specificity values; sample 
evaluation was not related to HCC; full papers were 
unavailable or the publication type was either letters to the 
editors, reviews, technical reports, case reports. Articles 
written in languages other than English and non-human 
studies were also excluded from the study.
Literature search
ASSIA, Cochrane library, EMbase, Medline, PubMed 
and the knowledge network Scotland were systematically 
searched. The search criteria included a combination 
of Mesh and string terms, for the following searches 
in each database:  (I)  (“l iquid biopsy” OR “liquid 
biopsies”) AND “Liver Neoplasms”(Mesh). (II) “Liver 
Neoplasms”(Mesh) AND (“cfdna” OR “cell-free DNA”); 
(III) “Liver Neoplasms”(Mesh) AND Neoplastic cells, 
Circulating”(Mesh). “Liver Neoplasms”(Mesh) was 
substituted with string terms “liver cancer”, “liver 
neoplasm”, “liver tumor”, “hcc”, and “primary liver tumor” 
in cases where the Mesh term could not be utilised.
There was no limit on the date of publication and the 
search was updated till February 2019.
Study selection and data extraction
PT, PM, LG conducted their database search independently.
Titles and abstracts were analysed and the studies were 
uploaded on to Rayyan QRCI (11) to be reviewed manually 
by the authors. The abstracts were screened on Rayyan 
QRCI and any disagreements on data extraction and quality 
assessment of the included studies were resolved through 
discussion and checked by MB. The final included studies 
were uploaded to Mendeley®, Elsevier, London, UK (12). A 
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flow chart for the inclusions and exclusions of this study is 
show in Figure 1.
Full text articles were matched in Mendeley and further 
examine using the criteria stated below.
The data extracted from the articles were publication 
year, participant demographics, experimental method, assay 
indicators, cut off values, CTC positivity, cancer stages and 
sensitivity and specificity scorings.
The data were then categorized and analysed based four 
distinct subgroup. They were (I) CTCs detected in serum; 
(II) CTC detection methodology; (III) low stage cancers; 
(IV) CTC detection rates and (V) group comparing the 
positivity rates of low and high stage cancers.
Quality assessment
The quality score of the studies were judged based on 
the Quality assessment of diagnostic accuracy studies 
(QUADAS) (13). The quality assessment is stratified into 
14 item phrased questions each with yes, no or unclear. The 
questions covered 4 domains patient selection, index test, 
reference standard, and flow and timing. Each domain is 
assessed in terms of risk of bias, and the first 3 domains are 
also assessed in terms of concerns regarding applicability. 
The maximum score is 14, a score of 7 or greater indicated 
a high-quality study, whilst less than 7 were of low quality 
(Table 1).
Statistical analysis
Statistical analysis was performed using the ‘Rev Man’ meta-
analysis soft ward for Windows. This software managed all 
the data and generated all the forest plots and the Moses-
Littenberg SROC curve.
The study performed the diagnostic accuracy test review 
by calculating the sensitivity and specificity of each test. The 
data was tabulated and produced a scatter plot (Figures 2,3). 
Using the Moses-Littenberg SROC curve on rev man a 
summary roc curve was produced for each data set which 
gives an indication for descriptive purposes (Figure 4).





















n Records retrieved through database search 
(Database: ASSIA, Cochrane library, EMbase, 
Medline, PubMed and the knowledge network ) 
(n=240)
Records after duplicates removed
(n=240)
Remaining records after screening by title 
(n=81)
Remaining records after screening by abstract
(n=59)
Remaining records after full-text articles assessed 
(n=35)
Studies included in quantitative synthesis (meta-analysis)
(n=35)





	Letter or reply (N=9)
Excluded (n=22)
 Metanalysis (N=3)
 Animal studies (N=3)
 Wrong outcomes (N=16)
Excluded (n=24)
 Foreign Language (N=3)
 Wrong outcomes (N=10)
 Full paper unavailable (N=6)
 2 were on hepatoma
 3 insufficient data
PRISMA 2009 Flow Diagram
Page 4 of 12 Translational Gastroenterology and Hepatology, 2021
© Translational Gastroenterology and Hepatology. All rights reserved. Transl Gastroenterol Hepatol 2021;6:54 | http://dx.doi.org/10.21037/tgh.2020.01.11




Patients M/F Sample Assay method Assay indicators Cutoff TP FP TN FN Sensitivity Specificity
Youden 
index
Aselmann et al. (14) 2001 6 66 NA Blood RT-PCR Methylation (AFP) 14 ng/mL 6 5 39 16 13 89 0.02
Bahnassy et al. (15) 2014 6 183 121/12 Blood RT-PCR Methylation (AFP) 7.5 ng/mL 115 5 57 6 96 91 0.87
2014 6 183 121/13 Blood RT-PCR Methylation (CD133) 73 ng/mL 48 72 4 59 40 6 0.54
2014 6 183 121/14 Blood RT-PCR Methylation (CK19) 49.8 ng/mL 105 15 51 12 87 81 0.72
2014 6 183 121/15 Blood RT-PCR Methylation (CD90) 400 ng/mL 99 21 56 7 83 90 0.68
Chang et al. (16) 2008 6 37 NA Plasma MS-PCR Methylation (APC) N/A 14 12 6 5 62 88 0.49
2008 6 37 NA Plasma MS-PCR Methylation (P16) N/A 15 9 4 9 79 50 0.20
2008 6 37 NA Plasma MS-PCR Methylation (GSTP1) N/A 13 6 6 12 68 67 0.35
2008 6 37 NA Plasma MS-PCR Methylation (RASSF1A) N/A 12 4 7 14 63 78 0.29
2008 6 37 NA Plasma MS-PCR Methylation (Ecadherin) N/A 18 14 1 4 98 22 0.41
Chen et al. (17) 2012 9 210 144/66 Blood qPCR Methylation (cfDNA) 213.8 ng/mL 69 11 103 27 86 79 0.54
Chen et al. (18) 2013 8 84 68/17 Serum Chemiluminescense Methylation (cfDNA) N/A 22 17 37 8 56 96 0.45
2013 8 84 68/18 Serum Chemiluminescense Methylation (AFP) N/A 21 18 36 9 54 91 0.42
2013 8 84 68/19 Serum Chemiluminescense Methylation (AFU) N/A 26 13 29 16 67 76 0.52
2013 8 84 68/20 Serum Chemiluminescense Methylation (cfDNA + AFP) N/A 28 11 34 11 72 87 0.65
2013 8 84 68/21 Serum Chemiluminescense Methylation (CFDNA + AFU) N/A 34 5 28 17 87 71 0.59
2013 8 84 68/22 Serum Chemiluminescense Methylation (CFDAN + AFP + AFU) N/A 35 4 25 20 90 64 0.58
Chu et al. (19) 2004 7 69 45/24 Serum MS-PCR Methylation (P16) N/A 22 4 19 24 48 83 0.30
Fu et al. (20) 2017 7 1647 NA Blood ELISA Methylation (Hsp90a) 62.44 ng/mL 838 66 4 677 93 90 0.67
2017 7 1647 NA Blood ELISA Methylation (AFP20 6.98 ng/mL 678 226 686 517 75 92 0.49
2017 7 1647 NA Blood ELISA Methylation (HSP90a+AFP) N/A 847 57 701 686 94 94 0.39
Han et al. (21) 2014 11 293 221/72 Blood MS-PCR Methylation (AFP) 20 ng/mL 93 46 87 67 58 48 0.20
2014 11 293 221/73 Blood MS-PCR Methylation (AFP) 200 ng/mL 49 7 126 111 31 92 0.06
2014 11 293 221/74 Blood MS-PCR Methylation (AFP) 400 ng/mL 39 1 132 121 24 99 0.23
2014 11 293 221/75 Blood MS-PCR Methylation (TRG5 + AFP) 20 ng/mL 130 54 79 30 81 39 0.23
2014 11 293 221/76 Blood MS-PCR Methylation (TRG5 + AFP) 200 ng/mL 109 19 114 51 68 78 0.47
2014 11 293 221/77 Blood MS-PCR Methylation (TRG5 + AFP) 400 ng/mL 104 13 120 56 65 85 0.50
Hosny et al. (22) 2008 8 255 NA Tissue PCR Methylation (249ser P53) NA 1 168 11 75 1 94 0.28
Huang et al. (23) 2003 8 75 67/18 Blood samples RT PCR Methylation (249ser P53) 254 ng/mL 10 6 44 15 40 88 0.80
Huang et al. (24) 2015 5 109 NA Serum Pyrosequencing Methylation (P16) 5% 49 8 35 17 65 87 0.38
2015 5 109 NA Serum Pyrosequencing Methylation (P16) 7% 33 2 41 33 39 97 0.53
2015 5 109 NA Serum Pyrosequencing Methylation (P16) 10% 18 1 42 48 20 99 0.36
Huang et al. (25) 2012 8 150 61/11 Plasma RQ-PCR Quantitative analysis of CfDNA 18 ng/mL 65 7 71 7 90 90 0.19
2012 8 150 61/12 Plasma RQ-PCR Quantitative analysis of CfDNA 143 ng/mL 43 29 49 29 60 78 0.07
Igetei et al. (26) 2008 8 162 NA Plasma Nested-PCR Methylation (249ser P53) N/A 6 0 77 79 7 100 0.43
Iizuka et al. (27) 2006 9 82 65/35 Serum Real-time PCR Quantitative analysis CfDNA 73 ng 36 16 14 16 69 93 0.63
Iizuka et al. (28) 2010 11 258 123/135 Serum MS-PCR Methylation (SRD5A2) NA 4 144 2 108 4 99 0.50
2010 11 258 123/135 Serum MS-PCR Methylation (SPINT2) NA 18 146 0 94 16 100 0.01
2010 11 258 123/135 Serum MS-PCR Methylation (AFP) 20 ng/mL 68 105 41 44 86 67 0.33
2010 11 258 123/135 Serum MS-PCR Methylation (PIVKA-2) 40 mAU/ml 59 138 8 53 89 70 0.50
Jeng et al. (29) 2004 7 111 57/54 Blood RT-PCR Methylation (AFP mRNA) 1,000 ng/mL 61 20 28 2 75 93 0.50
Table 1 (continued)
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Patients M/F Sample Assay method Assay indicators Cutoff TP FP TN FN Sensitivity Specificity
Youden 
index
Ji et al. (30) 2014 9 289 100/21 Serum MS-PCR Methylation (MT1G) NA 85 36 6 62 70 91 0.50
Jiang et al. (31) 2015 8 205 NA Serum/plasma RT-PCR Methylation (HBB) 76 14 32 83 80 94 0.50
Julich-Haertel et al. 
(32)
2017 8 517 310/145 Serum/plasma Fluorescence Methylation (taMPs) 9.3 63 23 355 76 73 82 0.50
2017 8 517 310/146 Serum/plasma Fluorescence Methylation (taMPs) 4.305 60 26 178 253 70 41 0.50
2017 8 517 310/147 Serum/plasma Fluorescence Methylation (taMPs) 4.125 70 16 202 229 81 47 0.50
Kirk et al. (33) 2000 8 119 97/22 Blood PCR Methylation (249ser P53) NA 19 5 61 34 36 92 0.50
Kuo et al. (34) 2014 8 83 NA Plasma MS-PCR Methylation (HOXA9) MI >0.88 23 14 42 7 73.3 97.1 0.50
Mohamed et al. (35) 2012 8 100 70/30 Serum Real-time PCR Methylation (RASSF1A) 640 nmol 36 25 35 4 90 55 0.50
Müller et al. (36) 1997 8 91 12-Jul Blood PCR Methylation (Albumin mRNA) NA 12 48 24 7 33 33 0.50
Piciocchi et al. (37) 2013 10 142 99/43 Plasma Real-time PCR Quantitative analysis CfDNA 1 ng 40 31 45 26 91 43 0.50
Ren et al. (38) 2006 8 119 NA Plasma Transilluminator Quantitative analysis CfDNA 36.6 ng 41 38 9 31 52 95 0.50
Schulze et al. (39) 2013 7 78 60/18 Blood CellSearch Methylation (EpCAM) 18 1 18 41 56 92 0.50
Sun et al. (40) 2013 10 93 36/7y Serum MS-PCR Methylation (TFPI2) NA 20 9 41 23 47 82 0.50
Tan et al. (41) 2007 8 18 NA Serum MS-PCR Methylation (RUNX3) NA 7 1 0 10 88 100 0.50
Witzigmann et al. (42) 2002 5 201 118/92 Blood RT-PCR Methylation (AFP mRNA) 24 3 113 61 73 53 0.50
Wong et al. (43) 2003 6 100 NA Serum/plasma MS-PCR Methylation (P16) NA 24 21 0 55 53 100 0.50
Briefs et al. (44) 1998 7 95 NA Serum/plasma MS-PCR Methylation (P16) NA 14 31 0 50 31 100 0.50
Yang et al. (45) 2005 6 130 NA Blood RT-PCR Methylation (AFPmRNA) 35 3 62 30 54 95 0.50
Okajima (46) 2017 8 110 79/31 Plasma RQ-PCR Quantitative analysis CfDNA 1.87×10 38 22 5 45 64 90 0.50
Yeo et al. (47) 2005 10 50 33/7y Plasma MS-PCR Methylation (RASSF1A) NA 17 23 0 10 43 100 0.50
Zhang et al. (48) 2013 8 58 30/28 Serum Chip/Pyrosequencing Methylation (DBX2) NA 28 3 3 24 88. 9 87 0.50
Zhang et al. (49) 2007 12 100 78/22 Serum MS-PCR Methylation (P16) NA 22 28 2 48 44 96 0.50
2007 12 58 78/23 Serum Chip/Pyrosequencing Methylation (THY1) NA 26 5 5 22 85 81 0.50
2007 12 100 78/24 Serum MS-PCR Methylation (P15) NA 11 39 0 50 22 100 0.50
2007 12 100 78/25 Serum MS-PCR Methylation (RASSF1A) NA 35 15 3 47 70 94 0.02
QUADAS, quality assessment of diagnostic accuracy studies; M/F, male/female; TP, true positive; FP, false positive; TN, true negative; FN, false negative.
Studies which compared CTC positivity in high and low 
stages of cancer were plot on a graph and compared (Figure 5).
Results
In this review, 240 studies were initially identified in the 
literature search. After analysing titles and abstracts, there 
were 181 studies excluded and 59 potential studies which 
were further reviewed. Of the 59 studies, 24 were excluded 
as they did not meet the inclusion criteria (Figure 1). Finally, 
35 studies were compliant with the inclusion criteria and 
were eligible for the meta-analysis (Table 1).
There were a total of 5,945 patients, of whom 2,344 
were male. All patients involve were diagnosed with HCC. 
Samples were taken from patient blood in 13 groups, serum 
in 12, plasma 7 in and 4 had samples taken from both serum 
and plasma.
All studies were published from 1994 onward. The flow 
chart of inclusion and exclusion studies is presented in the 
figure below. The average quadas score was 7.8 with lowest 
at 5 and highest 12.
From the forty one [41] studies, twenty four [24] 
evaluated the use of a tumour specific single gene 
methylation. Eleven trials assessed patients of the same 
cancer stage comparing the positivity rates of each CTC 
demonstrated in graphical form (Figure 4).
In addition, the method of CTC detection was 
analysed. There were 5 methods of analysis including 
chemiluminescence [variation of the standard enzyme 
immunoassay (EIA), which is a biochemical technique used in 
immunology], ELISA, MS-PCR and Real-time polymerase 
chain reaction (RT PCR). These methods of analysis had 
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Figure 2 Forest plots of estimates of sensitivity and specificity for the different markers (14-21,23-29,33,35) constituting liquid biopsy 
(37,38,42-47,49).
Various assay method for AFP
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Fu Y 2017 (AFP20) [20]
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Figure 3 Forest plots of estimates of sensitivity and specificity for the different assay methodology (14,15,18,20,21,28,29,42,47).
6 studies, 3 studies, 15 studies and 15 studies respectively.
Sensitivity and specificity of different circulating  
tumor cells
Four studies observed the 249 ser p53 CTC, which all have 
high specificity >0.8 but moderate to low sensitivity which 
is indicated on part of the roc curve. Alpha feto protein 
(AFP) has 8 studies all of which have moderate to high 
sensitivity and a high specificity >0.6. Circulating free DNA 
(CfDNA) has 4 studies with high the highest sensitivity 
and specificity, most of the studies above 0.6. cFDNA show 
promising result in comparison to the other liquid biopsy. 
P16 and Ras association domain-containing protein 1 
(RASSF1A) had the lowest sensitivity and specificity. The 
SROC curves were incomplete denoting uncertainty. The 
observed data is presented graphically on the forest plot 
(Figure 3) and SROC curve (Figure 5). Further analysis 
demonstrated that CD133, CK19, CD90 could be used to 
provide discriminatory values between the early and late 
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Figure 5 SROC curve for different circulating tumour cells.
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stages as shown in Figure 6.
Sensitivity and specificity for different assay methodology
Reverse transcription polymerase chain reaction had 
the highest sensitivity for AFP with sensitivity of 97% 
whilst MS PCR had the highest specificity of 99%. 
Chemiluminescence and Elisa had moderate sensitivity 
70%, 67% and specificity 57% and 75 % respectively. 
Most of the other CTC studies used RT- PCR, a total of 
15 studies were identified. RT PCR shown to produce a 
high specificity above 0.6 but a moderate sensitivity.
Positivity of early vs. late stages cancers in CTC detection
AFP mRNA, cytokeratin-19 (Ck19), cluster differentiation 
(CD90), cfDNA and tissue factor pathway inhibitor-2 
(TFPI2) all indicated CTC show a higher percentage of 
positivity in later stages in comparison to earlier stages. 
There was a difference of 6%, 44%, 27%, 5% and 13% 
respectively. However other CTC such as cfDNA show no 
difference. Interesting MT1G shows higher positivity in 
lower stages in comparison to higher stages.
Sensitivity and specificity for the different cutoff values
Han et al. (21) and Huang et al. (24) explored the effect 
of various cut off to the sensitivity and specificity of the 
diagnostic test. In the study of AFP, a higher cut off levels 
(400 ng/mL) was found to be more specific (99%) to lower 
levels (20 ng/mL) (65%), whilst being less sensitive (24% to 
58%). Similar results were seen in TRG5+ AFP (specificity 
of 90% to 65% and sensitivity of 65% to 81%) and P16 
INK4A (specificity of 98% to 81% and sensitivity of 27% 
to 74%) (Figure 4).
Youden index
Youden index is summary statistic of the roc curve used in the 
interpretation and evaluation of biomarkers. A value of zero 
indicates the diagnostic test gives a positive result for those 
with or without the disease and a value of 1 indicates no false 
positive or false negative. An acceptably benchmark is 0.50 (50). 
In this study, the highest index of 0.87 was produced by 
Bahnassy et al. (15) who studied AFP. In contrast, Iizuka 
et al. (28) analyzed SPINT2 that was found to have the 
lowest index of 0.01. The average index amongst all CTC 
was 0.46 with a mode and median of 0.5. In comparing, 5 
most common CTC that is AFP, 249serP54, P16, RASSF1A 
and cfDNA, CfDNA had the highest average index of 0.53 
followed by RASSF1A (0.41), P16 (0.40). Both AFP and. 
249serP54 had the worst overall index of 0.28 (Table 1).
Discussion
Blood based biomarkers could have promising value in early 
CTC percentage in high and low stages
CTC percentage in low stage 
CTC percentage in high stage
CTC percentage in low stage 
CTC Percentager in high stage
AFP
CD133 CK19 CD90 TRG5 MT1G TFPI2cfDNA cfDNAative ative
mRNA
Witzigm Bahnass Bahnass Bahnass Han




ann y (2) y (3) y (4) et al.et al. et al.
20.00 0.00 56.00 33.00 46.00 77.00 53.0045.00 46.0053.00 60.00














Figure 6 Positivity of CTC in late stages (3&4) and early stages (1&2). CTC, circulating tumour cell.
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diagnosis of HCC and therefore allow prompt treatment (51). 
It could be used a less-invasive alternative to current 
approach in diagnosis. However despite the range of CTC 
currently under investigation (52), there is variation in the 
reported diagnostic accuracy and the lack of standardized 
technical approach has contributed to the lack of consensus.
In a recent update in the Cochrane methods of screening 
and diagnostics tests, the current statistical model used in 
meta-analysis of diagnostic accuracy is SROC curves and 
the use of pooled sensitivity and specificity is considered an 
accurate method of reporting of such data (53).
The following criteria was used to evaluate the pooled 
sensitivity and specificity: high (0.6–1), moderate (0.4–0.59), 
low (<0.4) (51). In this meta-analysis we found that AFP 
has the highest overall diagnostic performance. The most 
common CTCs currently studied (249ser P53, P16, cfDNA 
and RASSF1A) have low to average Youden Index 0.28 to 
0.56. Interestingly whilst Bahnassy et al. (15) demonstrated 
the highest overall Youden index using AFP, the average 
index of AFP was 0.28. This may result from different 
cutoff used or assay method. Further studies are needed to 
better understand this.
From our available statistical analysis, the study 
demonstrated that liquid biopsies have a high sensitivity/
specificity however there is several limitations. This study 
has identified several heterogenous variables such as the 
follows: First demographic data (age, sex and race), sample 
size and etiology of HCC which was missing in the data. 
In addition, the underlying etiology of HCC was variable 
among and within studies.
There were inconsistencies in cut off values used for 
individual CTC’s, therefore the sensitivity and specificity 
could have been over or underestimated as shown in Figure 4. 
Unsurprisingly, the higher the cutoff value the higher the 
specificity but lower sensitivity due to higher rates of false 
negatives. For future studies, a singles cutoff value should be 
determined for each CTC to reduce outcome bias.
In addition, assay methods for CTC detection have 
shown to produce different results for the same type 
of liquid biopsy. A different cutoff value and varied 
experimental set up may account for these findings, 
however from our results we can take into consideration 
that different CTC detection methods of the same CTC 
may potentially create bias. Currently the standard for 
CTC detection immunocytochemistry (ICC) and reverse 
transcriptase polymerase chain reaction (RT-PCR).
We were unable to identify complete data sets. True positive, 
false positive, True Negative or false negative of various articles 
were calculated using the available sensitivity and specificity.
Finally our study sample size per CTC was too small 
which limited our ability to complete a full SROC curve 
thus the analysis from the SROC curve provided in this 
study was descriptive.
Overall, there is potential in the use of CTC however 
the lack of a standardized procedure in the study of CTC 
contributes to the lack of consensus of its use.
Future research should include large scaled, standardized 
studies for the diagnostic accuracy of CTC. Only when such 
a challenge is met should it be translated these promising 
results to clinical practice.
Conclusions
The CTC markers have variable sensitivity and specificity 
for HCC. CD133 and CK19 could potentially be used 
to differentiate early versus late stages irrespective to the 
morphology. Further studies are required to establish it use as 
an isolated test for detection. Therefore, in the current clinical 
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